The tirzepatide vs semaglutide trial results now include the first direct head-to-head comparison ever conducted between these two medications. Prior to 2025, all clinical comparisons were indirect, drawing inferences from separate trials run in different populations under different conditions. SURMOUNT-5 changed that. Published in the New England Journal of Medicine in July 2025, it provided the controlled, randomized evidence needed to directly compare efficacy and tolerability.

Why No Head-to-Head Trial Existed Before SURMOUNT-5

Tirzepatide received FDA approval as Mounjaro for type 2 diabetes in May 2022. Its obesity indication, Zepbound, arrived in November 2023. Semaglutide's obesity indication (Wegovy) arrived in June 2021, and its diabetes formulation (Ozempic) in December 2017. The two drugs entered the market at different times, with separate trial programs designed to demonstrate efficacy against placebo, not against each other.

Indirect comparisons from the STEP program (semaglutide) and the SURMOUNT program (tirzepatide) consistently showed greater weight loss with tirzepatide, but cross-trial comparisons are inherently limited. Different populations, different eligibility criteria, different timepoints, and different trial designs all introduce confounding that a direct randomized trial eliminates.

SURMOUNT-5: Trial Design

SURMOUNT-5 was a multicenter, randomized, open-label, phase 3b trial. It enrolled 751 adults with obesity but without type 2 diabetes. Those with a BMI of 27 kg/m² or greater qualified if they had at least one obesity-related comorbidity. Eligible comorbidities included hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. The mean age was 44.7 years, and 64.7% were women.

Participants were randomized 1:1 to receive tirzepatide or semaglutide subcutaneously once weekly for 72 weeks. Tirzepatide was titrated to the maximum tolerated dose of 10 mg or 15 mg. Semaglutide was titrated to the maximum tolerated dose of 1.7 mg or 2.4 mg. Both drugs were dosed at maximum tolerated doses rather than fixed doses, which is clinically relevant since it reflects how these medications are actually used in practice.

Primary Endpoint: Weight Loss at 72 Weeks

The trial's primary endpoint was the percentage change in body weight from baseline to week 72. This was measured using the least-squares mean method to account for missing data. Tirzepatide produced a least-squares mean weight reduction of 20.2% (95% CI: −21.4 to −19.1). Semaglutide produced a least-squares mean weight reduction of 13.7%. The difference was statistically significant and clinically substantial.

In absolute terms, this translated to mean weight losses of approximately 50.3 lbs with tirzepatide versus 33.1 lbs with semaglutide.

Secondary Endpoints

All five prespecified key secondary endpoints favored tirzepatide. The proportions of participants achieving weight reductions of at least 10%, 15%, 20%, and 25% were all significantly greater in the tirzepatide group. At the ≥25% weight reduction threshold, 31.6% of tirzepatide participants achieved this level.

Waist circumference reduction at week 72 was −18.4 cm with tirzepatide versus −13.0 cm with semaglutide. Improvements in cardiometabolic risk markers including systolic and diastolic blood pressure, HbA1c, fasting insulin, triglycerides, and HDL cholesterol all showed greater improvement in the tirzepatide group. A post-hoc cardiovascular analysis published in September 2025 estimated that tirzepatide was associated with a greater predicted 10-year cardiovascular risk reduction. The absolute reduction was 2.4% with tirzepatide versus 1.4% with semaglutide. This post-hoc cardiovascular analysis does not constitute a cardiovascular outcomes trial. Semaglutide has its own dedicated cardiovascular outcomes evidence from the SELECT trial, which demonstrated reduced major adverse cardiovascular events in adults with obesity and established cardiovascular disease. A comparable tirzepatide cardiovascular outcomes trial has not yet been fully reported. The two drugs' cardiovascular evidence bases are therefore not currently symmetric, which is a relevant clinical consideration when selecting between them for patients with significant cardiovascular risk.

Tolerability in SURMOUNT-5

Most adverse events in both groups were mild to moderate and occurred primarily during dose escalation. GI adverse events leading to treatment discontinuation were observed in 5.6% of semaglutide participants versus 2.7% of tirzepatide participants. This tolerability difference reflects the antiemetic contribution of GIP receptor co-agonism. Preclinical research from the University of Pennsylvania published in September 2025 described this mechanism in detail.

What the Trial Does and Doesn't Prove

SURMOUNT-5 establishes tirzepatide's superior efficacy and better GI tolerability profile compared to semaglutide at maximum tolerated doses. These are the specific conditions under which this comparison applies.

The trial has important limitations to acknowledge. It was open-label, meaning participants and investigators knew which drug each participant was receiving. This is a design limitation that can introduce bias, particularly for subjective outcomes, though weight loss is a reasonably objective primary endpoint. The trial was funded by Eli Lilly, the manufacturer of tirzepatide. This is standard disclosure practice and doesn't invalidate the peer-reviewed findings, but it's contextually important.

SURMOUNT-5 enrolled adults without type 2 diabetes. Tirzepatide results in type 2 diabetic populations are well-documented in the SURPASS program but are not directly compared to semaglutide in the SURMOUNT-5 data. SURMOUNT-5 did include a higher proportion of men (35%) than most obesity trials. The investigators note this as a factor in the trial's slightly lower absolute weight loss compared to what SURMOUNT-1 produced.

Context: Indirect Comparisons Before SURMOUNT-5

Prior to SURMOUNT-5, the available evidence came from indirect comparisons. SURMOUNT-1 showed tirzepatide producing up to 22.5% weight loss at 15 mg over 72 weeks in non-diabetic obese adults. STEP-1 showed semaglutide producing 14.9% weight loss at 2.4 mg over 68 weeks in a similar population. Pooled and network meta-analyses consistently showed tirzepatide outperforming semaglutide across multiple weight reduction thresholds.

SURMOUNT-5 confirms and quantifies what indirect comparisons suggested: tirzepatide produces meaningfully greater weight loss than semaglutide at comparable maximum doses. The 6.5 percentage point difference in SURMOUNT-5 is smaller than indirect comparisons suggested, partly reflecting the higher male enrollment and different patient characteristics.

The indirect comparison path from STEP to SURMOUNT trials had a significant structural limitation. STEP-1 ran for 68 weeks. SURMOUNT-1 ran for 72 weeks. Their eligibility criteria differed slightly. The patient populations were drawn from different geographies and time periods. Any cross-trial comparison must acknowledge these differences rather than treating the numbers as directly equivalent. SURMOUNT-5 eliminates this problem by placing both drugs in a single controlled study with identical eligibility criteria, the same outcome measures, and the same assessment timepoints.

THRYVE Wellness Medical's Approach

THRYVE Wellness Medical's Functional Medicine team stays current with the evolving evidence from both the SURMOUNT and SURPASS trial programs. Their comprehensive Biomarker Testing approach evaluates each patient's complete metabolic and hormonal profile before making individualized decisions about which medication is most appropriate. The SURMOUNT-5 data is one input into that decision alongside each patient's cardiovascular history, GI tolerance, comorbidities, and treatment goals.

Frequently Asked Questions

What did the tirzepatide vs semaglutide head-to-head trial show?
SURMOUNT-5 showed tirzepatide produced 20.2% mean body weight reduction versus 13.7% with semaglutide at 72 weeks. Tirzepatide also showed better GI tolerability (2.7% vs 5.6% GI-related discontinuation).

Was SURMOUNT-5 a fair comparison?
The trial used maximum tolerated doses for both drugs, reflecting real clinical use. It was open-label and funded by Eli Lilly, which are standard disclosures. The NEJM peer-review process and independent data review support confidence in the results.

Does SURMOUNT-5 apply to people with type 2 diabetes?
No. SURMOUNT-5 enrolled adults without diabetes. Separate trials have evaluated both drugs in type 2 diabetes populations, but SURMOUNT-5's specific findings apply to obese adults without diabetes.

How much more weight loss does tirzepatide produce than semaglutide?
In SURMOUNT-5, tirzepatide produced 20.2% versus 13.7% weight loss — a difference of approximately 6.5 percentage points. This translated to roughly 17 lbs more weight loss on average.

Were both drugs in SURMOUNT-5 at their full doses?
Both drugs were titrated to maximum tolerated doses, meaning participants escalated as high as they could based on individual tolerance. This is how both medications are used in clinical practice.

Key Takeaways

SURMOUNT-5 was the first randomized head-to-head trial directly comparing tirzepatide and semaglutide in adults with obesity without diabetes. At 72 weeks, tirzepatide produced 20.2% mean weight loss versus 13.7% with semaglutide. All five key secondary endpoints, including weight reduction thresholds of 10%, 15%, 20%, and 25%, favored tirzepatide. GI-related discontinuation was lower with tirzepatide (2.7% vs 5.6%). The trial was open-label and funded by Eli Lilly, which are contextually important disclosures alongside the peer-reviewed NEJM publication.

The Bottom Line

SURMOUNT-5 in the New England Journal of Medicine provides the first direct controlled evidence that tirzepatide produces greater weight loss with better GI tolerability. It confirms and quantifies the advantage suggested by indirect comparisons across separate trial programs. Understanding what the trial measures and its specific population gives the most accurate context for applying the results to individual patient decisions.